We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Thyroid Cancer Treatment in Adolescents and Young Adult Women: Impact on Reproductive Outcomes in a Population-Based Cohort

MedXY Editorial Team•Dec 25, 2025•Clinical Updates
infertilitythyroid cancer

Highlights

  • All types of thyroid cancer treatment in adolescent and young adult women increase infertility diagnosis and early menopause risk.
  • No significant associations were observed between thyroid cancer treatments and premature ovarian insufficiency (POI) or decreased childbirth rates.
  • Large, population-based matched cohort study provides robust real-world insights spanning nearly three decades.
  • Findings underscore the importance of reproductive counseling and long-term surveillance in young women undergoing thyroid cancer treatments.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Linking Female Infertility History to Type 2 Diabetes Risk: Insights from the Nurses’ Health Study IIThis study explores the increased risk of type 2 diabetes among women with a history of infertility, highlighting specific infertility causes and implications independent of BMI.Sep 6, 2026The Thyroid Cancer Modified Anxiety Scale (TC-MAX): A Novel Tool to Assess Cancer-Related Distress and Guide Patient-Centered CareThe TC-MAX is the first validated, disease-specific instrument measuring thyroid cancer-related anxiety, showing strong reliability and validity to inform treatment decisions and improve patient-centered care.Aug 12, 2026Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort AnalysisThis retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.Aug 4, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents
Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control r
Jun 28, 2026
Validation of the 2025 ATA Risk Stratification System in a Cohort of Patients with Papillary Thyroid CarcinomaA real-world study validates the 2025 ATA thyroid cancer risk guidelines, showing significant patient reclassification and identifying a new ‘low-intermediate-risk’ group needing tailored management approaches.Apr 18, 2026
Three Modifiable Factors Predict Emotional Impairment in Thyroid Cancer Patients: What Clinicians Need to KnowA prospective study identifies exhaustion, head and neck discomfort, and body image concerns as independent predictors of poor emotional functioning in differentiated thyroid carcinoma patients. These findings highlight actionable targets fApr 13, 2026